

Assessment of the mechanism of growth inhibition of *Staphylococcus aureus* by a Bowman-Birk inhibitor purified from *Lutzelburgia auriculata* seeds using Scanning Electron Microscopy

Martins, T. F.; Albuquerque, L. M.; Vasconcelos, I. M.; Silva, R. G. G.; Silva, F. D. A.; Souza, P. F. N.; Oliveira, J. T. A.

Dep. de Bioquímica e Biologia Molecular, UFC, CE; Brasil

INTRODUCTION: *Staphylococcus aureus* has become a major global health problem and a trouble to healthcare systems mainly due to increasing hospital-acquired infection and the spread of multidrug-resistant bacteria. Therefore, new strategies of treatment are needed, either by chemical modification of existing drugs or purification of novel biomolecules with effective antibacterial activity. Plant protease inhibitors are proteins of low molecular weight that is involved in various important physiological functions like regulators of endogenous proteinases and defense mechanism. They also have received special attention due to their biological properties with potential as therapeutic agents. **OBJECTIVES:** To assess the mechanism by which a Bowman-Birk inhibitor purified from *Lutzelburgia auriculata* seeds (LzaBBI) inhibits *Staphylococcus aureus* growth. **MATERIAL AND METHODS:** To purify LzaBBI, the seed extract was boiled, centrifuged and the supernatant loaded on a Sepharose®-4B-anhydrotrypsin affinity column, followed by reverse phase chromatography of the active protein fractions. Bacteria were exposed to LzaBBI (10 µg) and the cells observed by Scanning Electron Microscopy (SEM) up to 5 h later to assess topological changes caused in *S. aureus* (ATCC 25923) cells induced by LzaBBI. **RESULTS AND DISCUSSION:** LzaBBI, at low concentrations, had negative impact on the *S. aureus* development. In control cells, not incubated with LzaBBI, the bacteria were normal. Contrary, upon incubation with LzaBBI, the bacterial cell surface presented dents, orifices and deformities, indicative of strong mechanical injuries. **CONCLUSION:** SEM analysis reveals that LzaBBI hinders the *S. aureus in vitro* development by damaging the cell structure. This property could be further exploited towards using LzaBBI as a new antibacterial agent in human or animal therapeutics.

Keywords: *Lutzelburgia auriculata*, Bowman-Birk inhibitor, *Staphylococcus aureus*

Supported by: UFC, CNPq, CAPES, Central Analítica-UFC, CT-INFRA, MCTI-SISNANO, Pró-Equipamentos CAPES